# A Safety Study of PF-08046045/SGN-35T in Adults With Advanced Cancers

> **NCT06120504** · PHASE1 · TERMINATED · sponsor: **Seagen, a wholly owned subsidiary of Pfizer** · enrollment: 22 (actual)

## Conditions studied

- Lymphoma, T-Cell, Cutaneous
- Hodgkin Disease
- Lymphoma, T-Cell, Peripheral
- Lymphoma, Large-Cell, Anaplastic
- Lymphoma, Large B-Cell, Diffuse
- Lymphoma, Non-Hodgkin

## Interventions

- **DRUG:** PF-08046045

## Key facts

- **NCT ID:** NCT06120504
- **Lead sponsor:** Seagen, a wholly owned subsidiary of Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2024-02-29
- **Primary completion:** 2025-12-10
- **Final completion:** 2025-12-10
- **Target enrollment:** 22 (ACTUAL)
- **Why stopped:** Study terminated as part of strategic considerations
- **Last updated:** 2026-01-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06120504

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06120504, "A Safety Study of PF-08046045/SGN-35T in Adults With Advanced Cancers". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06120504. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*